ERBB2 and breast carcinoma: It is estimated that 15–20% of human breast cancers may overexpress a molecule called Human epidermal growth factor receptor-2 (HER-2) oncogene, which is associated with poor prognosis and a high recurrence rate [3,4,5,6,7].